| Literature DB >> 31630195 |
Muthiah Bose1, Juliane Sachsenweger1,2, Niina Laurila1, Ann Christin Parplys3, Jonas Willmann3, Johannes Jungwirth4, Marco Groth5, Katrin Rapakko6, Pentti Nieminen7, Thomas W P Friedl2, Lisa Heiserich8, Felix Meyer3, Hanna Tuppurainen1, Hellevi Peltoketo1, Heli Nevanlinna9, Katri Pylkäs1, Kerstin Borgmann3, Lisa Wiesmüller2, Robert Winqvist1, Helmut Pospiech4,10.
Abstract
Whilst heterozygous germline mutations in the ABRAXAS1 gene have been associated with a hereditary predisposition to breast cancer, their effect on promoting tumourigenesis at the cellular level has not been explored. Here, we demonstrate in patient-derived cells that the Finnish ABRAXAS1 founder mutation (c.1082G > A, Arg361Gln), even in the heterozygous state leads to decreased BRCA1 protein levels as well as reduced nuclear localization and foci formation of BRCA1 and CtIP. This causes disturbances in basal BRCA1-A complex localization, which is reflected by a restraint in error-prone DNA double-strand break repair pathway usage, attenuated DNA damage response and deregulated G2-M checkpoint control. The current study clearly demonstrates how the Finnish ABRAXAS1 founder mutation acts in a dominant-negative manner on BRCA1 to promote genome destabilization in heterozygous carrier cells.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31630195 DOI: 10.1093/hmg/ddz252
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 6.150